Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn’s disease patients: the usefulness of rapid testing.

Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn’s disease patients: the usefulness of rapid testing. Aliment Pharmacol Ther. 2018 Aug 15;: Authors: Verstockt B, Moors G, Bian S, Van Stappen T, Van Assche G, Vermeire S, Gils A, Ferrante M Abstract BACKGROUND: Proactive testing of adalimumab serum levels is debated. AIM: To study the association between adalimumab serum levels at week 4 and the development of anti-adalimumab drug antibodies and long-term outcome in anti-TNF naive Crohn’s disease patients. METHODS: Serum samples from 116…

Read More

Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease.

Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Jul 31;: Authors: Kotze PG, Ma C, Almutairdi A, Al-Darmaki A, Devlin SM, Kaplan GG, Seow CH, Novak KL, Lu C, Ferraz JGP, Stewart MJ, Buresi M, Jijon H, Mathivanan M, Heatherington J, Martin ML, Panaccione R Abstract BACKGROUND: Vedolizumab is an α4β7 integrin antagonist with proven efficacy for inducing and maintaining clinical response and remission in Crohn’s disease (CD) and ulcerative colitis (UC). AIM: To evaluate clinical and objective response…

Read More

Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn’s Disease: A Bayesian Network Meta-analysis: Republished.

Related Articles Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn’s Disease: A Bayesian Network Meta-analysis: Republished. Inflamm Bowel Dis. 2017 May 01;23(5):E26-E37 Authors: Coward S, Kuenzig ME, Hazlewood G, Clement F, McBrien K, Holmes R, Panaccione R, Ghosh S, Seow CH, Rezaie A, Kaplan GG Abstract Background: Induction treatment of mild-to-moderate Crohn’s disease is controversial. Purpose: To compare the induction of remission between different doses of mesalamine, sulfasalazine, corticosteroids, and budesonide for active Crohn’s disease. Data sources: We identified randomized controlled trials from…

Read More

Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn’s Disease: A Bayesian Network Meta-Analysis: ERRATUM.

Related Articles Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn’s Disease: A Bayesian Network Meta-Analysis: ERRATUM. Inflamm Bowel Dis. 2017 May 01;23(5):E25 Authors: PMID: 30052984 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30052984?dopt=Abstract

Read More

Meta-Analysis: The Influence of Preoperative Infliximab Use on Postoperative Complications of Crohn’s Disease.

Meta-Analysis: The Influence of Preoperative Infliximab Use on Postoperative Complications of Crohn’s Disease. Inflamm Bowel Dis. 2018 Jul 24;: Authors: Xu Y, Yang L, An P, Zhou B, Liu G Abstract Background: Infliximab (IFX) is a breakthrough treatment for refractory Crohn’s disease (CD) whose effect on postoperative complications of CD remains controversial. The purpose of this study was to conduct a meta-analysis examining the effect of IFX on postoperative complications of CD. Methods: We searched “PubMed,” “EMBASE,” and “Cochrane Library” databases from inception of each database until March 2018. All…

Read More

Corrigendum to Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study.

Corrigendum to Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study. Inflamm Bowel Dis. 2018 Jul 17;: Authors: PMID: 30016430 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30016430?dopt=Abstract

Read More

Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease.

Related Articles Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease. Dig Dis Sci. 2018 Jul 13;: Authors: Juncadella A, Papamichael K, Vaughn BP, Cheifetz AS Abstract BACKGROUND: A treat-to-target therapeutic approach is emerging as the new standard of care for treating inflammatory bowel disease (IBD), Crohn’s disease (CD), and ulcerative colitis (UC). AIMS: We aimed to investigate the association of serum adalimumab concentrations during maintenance therapy with biochemical, endoscopic, and histologic remission in IBD. METHODS: This retrospective multicenter study included consecutive IBD patients…

Read More
<< Go Back